Pneumonias 10 studies with 5550 participants (3239 on biologics) reported results on pneumonias during the study period, demonstrating that the use of biologics was associated with an overall trend of a 30% reduction of pneumonias compared to the control group (risk ratio 0.70, 95% CI 0.36–1.37, I 2 =0%) ( supplementary figure S22 ).
← all excerpts
Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials.
2
—
—
The sentences
Change in ACT score Three studies with 688 participants reported the efficacy of omalizumab on the change in ACT, with a trend for improvement by 0.58 points (95% CI −0.12–1.29); however, they did not reach statistical significance or the MCID (three points for adults and two points for patients aged 12–18 years) ( supplementary figure S14 ) [ 67 , 68 ].